Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy and toxicity of adding cetuximab to chemotherapy in the treatment of metastatic colorectal cancer: a meta-analysis from 12 randomized controlled trials.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine - 1 Dec 2014

Lv Zhong-Chuan, Ning Jin-Yao, Chen Hong-Bing

Abstract excerpt

Cetuxiamb, a monoclonal antibody against epidermal growth factor receptor (EGFR), has been used in combination with chemotherapy for patients with metastatic colorectal cancer (mCRC). However, the efficacy of combined therapies of cetuximab and different chemotherapy regimens remains controversial. Therefore, we conducted a meta-analysis to evaluate the efficacy and toxicity of adding cetuximab to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cetuximab

Share to Neoplasm Metastasis

Share to Proto-Oncogene Proteins p21(ras)

Share to Publication Bias

Share to Randomized Controlled Trials as Topic

Share to ras Proteins

Source

Identifiers

PMID: 25417200
DOI: 10.1007/s13277-014-2227-z

Genes

KRAS
BRAF
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy and toxicity of adding cetuximab to chemotherapy in the treatment of metastatic colorectal cancer: a meta-analysis from 12 randomized controlled trials.PMID 25417200Read ↗

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.Semantic proximity Read ↗

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.Semantic proximity Read ↗

Standard chemotherapy with cetuximab for treatment of colorectal cancer.Semantic proximity Read ↗

Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials.Semantic proximity Read ↗

Effect of BRAF V600E mutation on tumor response of anti-EGFR monoclonal antibodies for first-line metastatic colorectal cancer treatment: a meta-analysis of randomized studies.Semantic proximity Read ↗

Cetuximab versus bevacizumab in metastatic colorectal cancer: a comparative effectiveness study.Semantic proximity Read ↗

Cetuximab-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of K-ras mutations.Semantic proximity Read ↗

Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: a meta-analysis.Semantic proximity Read ↗

How do we optimally use cetuximab in first-line treatment for metastatic colorectal cancer?Semantic proximity Read ↗

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.Semantic proximity Read ↗

Impact of cetuximab in current treatment of metastatic colorectal cancer.Semantic proximity Read ↗

Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.